Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Michel de Weers"'
Autor:
Michael. S. van der Veer, Michel de Weers, Berris van Kessel, Joost M. Bakker, Shulamiet Wittebol, Paul W.H.I. Parren, Henk M. Lokhorst, Tuna Mutis
Publikováno v:
Haematologica, Vol 96, Iss 2 (2011)
Background In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab. Daratumumab is a novel human CD38 monoclonal antibo
Externí odkaz:
https://doaj.org/article/515b5bb2f7ff4ba8b6cc79f2555c3580
Autor:
Michel de Weers, Paul W. H. I. Parren, Henk Rozemuller, Frans M. A. Hofhuis, Petra Moerer, Anton C.M. Martens, Henk M. Lokhorst, Jeroen F. van Velzen, Ellen van Binsbergen, Berris van Kessel, Joost D. de Bruijn, Richard W.J. Groen, Reinier Raymakers, Linda Aalders, Huipin Yuan, Arjan Buijs, Willy A. Noort, Andries C. Bloem, Tuna Mutis, Jan Jacob Schuringa, Henk-Jan Prins
Publikováno v:
Blood, 120(3), e9-e16. American Society of Hematology
Groen, R W J, Noort, W A, Raymakers, R A, Prins, H-J, Aalders, L, Hofhuis, F M, Moerer, P, van Velzen, J F, Bloem, A C, van Kessel, B, Rozemuller, H, van Binsbergen, E, Buijs, A, Yuan, H, de Bruijn, J D, de Weers, M, Parren, P W H I, Schuringa, J J, Lokhorst, H M, Mutis, T & Martens, A C M 2012, ' Reconstructing the human hematopoietic niche in immunodeficient mice : opportunities for studying primary multiple myeloma ', Blood, vol. 120, no. 3, pp. e9-e16 . https://doi.org/10.1182/blood-2012-03-414920
Blood, 120(3), E9-E16. AMER SOC HEMATOLOGY
Groen, R W J, Noort, W A, Raymakers, R A, Prins, H-J, Aalders, L, Hofhuis, F M, Moerer, P, van Velzen, J F, Bloem, A C, van Kessel, B, Rozemuller, H, van Binsbergen, E, Buijs, A, Yuan, H, de Bruijn, J D, de Weers, M, Parren, P W H I, Schuringa, J J, Lokhorst, H M, Mutis, T & Martens, A C M 2012, ' Reconstructing the human hematopoietic niche in immunodeficient mice : opportunities for studying primary multiple myeloma ', Blood, vol. 120, no. 3, pp. e9-e16 . https://doi.org/10.1182/blood-2012-03-414920
Blood, 120(3), E9-E16. AMER SOC HEMATOLOGY
Interactions within the hematopoietic niche in the BM microenvironment are essential for maintenance of the stem cell pool. In addition, this niche is thought to serve as a sanctuary site for malignant progenitors during chemotherapy. Therapy resista
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33c149343f1eb6720f867cbf4dec702f
https://doi.org/10.1182/blood-2012-03-414920
https://doi.org/10.1182/blood-2012-03-414920
Autor:
Berris van Kessel, Tuna Mutis, Paul W. H. I. Parren, Michel de Weers, Shulamiet Wittebol, Henk M. Lokhorst, Michael S. van der Veer, Joost M. Bakker
Publikováno v:
Haematologica, 96(2), 284-290. Ferrata Storti Foundation
van der Veer, M S, de Weers, M, van Kessel, B, Bakker, J M, Wittebol, S, Parren, P W H I, Lokhorst, H M & Mutis, T 2011, ' Towards effective immunotherapy of myeloma enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab ', Haematologica, vol. 96, no. 2, pp. 284-290 . https://doi.org/10.3324/haematol.2010.030759
van der Veer, M S, de Weers, M, van Kessel, B, Bakker, J M, Wittebol, S, Parren, P W H I, Lokhorst, H M & Mutis, T 2011, ' Towards effective immunotherapy of myeloma enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab ', Haematologica, vol. 96, no. 2, pp. 284-290 . https://doi.org/10.3324/haematol.2010.030759
Background: In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab. Daratumumab is a novel human CD38 monoclonal antib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da88e4ee53843c96a326b21d352c3744
https://doi.org/10.3324/haematol.2010.030759
https://doi.org/10.3324/haematol.2010.030759
Autor:
Judith G. M. Rosmalen, Michel de Weers, Willem van Ewijk, Paul P. Knegt, Luciënne Speleman, Femke Muskens, Jane S. A. Voerman, Katarina Radošević, Annabrita Hemmes
Publikováno v:
Journal of Immunological Methods, 272, 219-233. Elsevier
For efficient screening of phage antibody libraries obtained by selection on whole cells, we have developed a modified colony lift assay using cell-coated filters. Both cells growing in suspension as well as adherent cells can be coated onto nitrocel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::863aca5bd7acd0f89e9d6b0eea0b8662
https://doi.org/10.1016/s0022-1759(02)00208-9
https://doi.org/10.1016/s0022-1759(02)00208-9
Autor:
Wim K. Bleeker, Matthias Peipp, Joost M. Bakker, Jan G. J. van de Winkel, Michel de Weers, Michael S. van der Veer, Kenneth C. Anderson, Paul W. H. I. Parren, Thomas Valerius, Yu-Tzu Tai, Jerry W. Slootstra, Tom Vink, Lukas A. Oomen, Tuna Mutis, Daniëlle C H Jacobs, Henk M. Lokhorst
Publikováno v:
De Weers, M, Tai, Y T, Van Der Veer, M S, Bakker, J M, Vink, T, Jacobs, D C H, Oomen, L A, Peipp, M, Valerius, T, Slootstra, J W, Mutis, T, Bleeker, W K, Anderson, K C, Lokhorst, H M, Van De Winkel, J G J & Parren, P W H I 2011, ' Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors ', Journal of Immunology, vol. 186, no. 3, pp. 1840-1848 . https://doi.org/10.4049/jimmunol.1003032
Journal of Immunology, 186(3), 1840-1848. American Association of Immunologists
Journal of Immunology, 186(3), 1840-1848. American Association of Immunologists
CD38, a type II transmembrane glycoprotein highly expressed in hematological malignancies including multiple myeloma (MM), represents a promising target for mAb-based immunotherapy. In this study, we describe the cytotoxic mechanisms of action of dar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a35212ba26b9a29a8ec88dd7dd78bdff
https://research.vumc.nl/en/publications/b6b6ee97-74dc-48a1-a8fe-33f5e327772b
https://research.vumc.nl/en/publications/b6b6ee97-74dc-48a1-a8fe-33f5e327772b
Autor:
Ruud K. B. Schuurman, Jacques J.M. van Dongen, Michel de Weers, Rudolf W. Hendriks, Rob G.J. Mensink, Margriet E. M. Kraakman, M. C. M. Verschuren
Publikováno v:
European Journal of Immunology. 23:3109-3114
X-linked agammaglobulinemia (XLA) is an immunodeficiency disease in man, resulting from an arrest in early B cell differentiation. The gene defective in XLA has recently been identified and encodes a cytoplasmic protein tyrosine kinase, named Bruton'
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e4c0f774af29dabd9c259ca1c9d625c
https://doi.org/10.1002/eji.1830231210
https://doi.org/10.1002/eji.1830231210
Autor:
Michel de Weers, Magreet Jonker, Christian Reiter, Nel Otting, Marcel Kenter, Ronald E. Bontrop, Jacqueline D.H. Anholts
Publikováno v:
Human Immunology. 36:205-218
Mhc-DRB and-DQA1 second-exon and-DRB 3′-untranslated-region nucleotide sequences of three lowland gorillas with no known family relationship with each other and of two HLA homozygous typing cell lines were determined and compared with published pri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4fbf4b2c0c02dde6d11d4572f92daa34
https://doi.org/10.1016/0198-8859(93)90127-m
https://doi.org/10.1016/0198-8859(93)90127-m
Autor:
Arnout F. Gerritsen, Paul W. H. I. Parren, Martijn Bosch, Jan G. J. van de Winkel, Michel de Weers
Publikováno v:
Journal of Immunological Methods, 352(1-2), 140-146. ELSEVIER SCIENCE BV
Complement-dependent cytotoxicity (CDC) represents an important Fc-mediated effector function of antibodies and is a quality often sought in candidates for therapeutic antibody development in cancer. Antibodies inducing potent CDC are relatively rare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c27c438668071fb2ea5d3f32319a8678
https://pubmed.ncbi.nlm.nih.gov/19891971
https://pubmed.ncbi.nlm.nih.gov/19891971
Autor:
Kate Sasser, Marije B. Overdijk, Paul W. H. I. Parren, Niels Kaldenhoven, Grietje Andringa, Jeroen J. Lammerts van Bueren, Danielle Jakobs, Antonio Ortiz Buijsse, Marleen Voorhorst, Parul Doshi, Sanne Hiddingh, Elke Gresnigt, Michel de Weers, Joyce I. Meesters, Luus Wiegman, Marcel Roza
Publikováno v:
van Bueren, J L, Jakobs, D, Kaldenhoven, N, Roza, M, Hiddingh, S, Meesters, J, Voorhorst, M, Gresnigt, E, Wiegman, L, Buijsse, A O, Andringa, G, Overdijk, M B, Doshi, P, Sasser, K, de Weers, M & Parren, P W H I 2014, ' Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79 ', Blood, vol. 124, no. 21, pp. 3474-3474, . https://doi.org/10.1182/blood.V124.21.3474.3474
The CD38 molecule, with its high expression on Multiple Myeloma (MM), is considered a suitable target for antibody therapy of MM. We developed daratumumab (DARA), a human CD38 monoclonal antibody (mAb) with direct and Fc-mediated cell killing activit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8596e4ba458060c8a13916ed36da048a
https://doi.org/10.1182/blood.v124.21.3474.3474
https://doi.org/10.1182/blood.v124.21.3474.3474
Autor:
Berris van Kessel, Joost M. Bakker, Michel de Weers, Paul W. H. I. Parren, Tuna Mutis, Inger S. Nijhof, Jeroen J. Lammerts van Bueren, Henk M. Lokhorst
Publikováno v:
Blood. 120:4988-4988
Abstract 4988 To date, multiple myeloma (MM) remains an incurable malignancy of antibody-producing clonal plasma cells. The introduction of a new generation of immunomodulatory agents, such as lenalidomide (LEN), and the potent proteasome inhibitor b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5721ff53a27ce32bc8b934ad0f67349
https://doi.org/10.1182/blood.v120.21.4988.4988
https://doi.org/10.1182/blood.v120.21.4988.4988